OrbiMed’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-330,000
| Closed | -$49.2M | – | 111 |
|
|
2023
Q3 | $49.2M | Buy |
+330,000
| New | +$48.4M | 1.04% | 32 |
|
|
2022
Q4 | – | Sell |
-600,000
| Closed | -$80.5K | – | 116 |
|
|
2022
Q3 | $80.5K | Sell |
600,000
-199,800
| -25% | -$28.7M | 1.49% | 23 |
|
|
2022
Q2 | $122K | Sell |
799,800
-115,800
| -13% | -$17.7M | 2.22% | 11 |
|
|
2022
Q1 | $148M | Sell |
915,600
-153,200
| -14% | -$22.3M | 2.41% | 11 |
|
|
2021
Q4 | $145M | Sell |
1,068,800
-351,800
| -25% | -$41.6M | 1.86% | 12 |
|
|
2021
Q3 | $153M | Buy |
1,420,600
+253,100
| +22% | +$28.9M | 1.68% | 17 |
|
|
2021
Q2 | $132M | Sell |
1,167,500
-45,700
| -4% | -$5.15M | 1.33% | 21 |
|
|
2021
Q1 | $131M | Buy |
1,213,200
+350,900
| +41% | +$37.5M | 1.23% | 22 |
|
|
2020
Q4 | $92.4M | Buy |
862,300
+398,300
| +86% | +$38.3M | 0.81% | 38 |
|
|
2020
Q3 | $40.6M | Hold |
464,000
| – | – | 0.51% | 58 |
|
|
2020
Q2 | $45.6M | Buy |
464,000
+235,000
| +103% | +$20.7M | 0.64% | 49 |
|
|
2020
Q1 | $17.4M | Buy |
+229,000
| New | +$19.5M | 0.29% | 71 |
|
|
2018
Q2 | – | Sell |
-1,527,500
| Closed | -$145M | – | 148 |
|
|
2018
Q1 | $145M | Buy |
1,527,500
+476,900
| +45% | +$52.4M | 1.79% | 16 |
|
|
2017
Q4 | $102M | Sell |
1,050,600
-914,400
| -47% | -$86.2M | 1.29% | 23 |
|
|
2017
Q3 | $175M | Sell |
1,965,000
-232,600
| -11% | -$17.7M | 1.67% | 18 |
|
|
2017
Q2 | $159M | Buy |
2,197,600
+117,600
| +6% | +$7.91M | 1.67% | 19 |
|
|
2017
Q1 | $136M | Sell |
2,080,000
-845,000
| -29% | -$53.1M | 1.54% | 20 |
|
|
2016
Q4 | $183M | Sell |
2,925,000
-1,304,900
| -31% | -$79.7M | 2.33% | 10 |
|
|
2016
Q3 | $267M | Sell |
4,229,900
-2,343,200
| -36% | -$152M | 3.04% | 6 |
|
|
2016
Q2 | $407M | Sell |
6,573,100
-822,600
| -11% | -$50.1M | 4.25% | 3 |
|
|
2016
Q1 | $422M | Sell |
7,395,700
-52,800
| -0.7% | -$2.94M | 4.45% | 5 |
|
|
2015
Q4 | $441M | Buy |
7,448,500
+505,300
| +7% | +$29.1M | 4% | 6 |
|
|
2015
Q3 | $378M | Buy |
6,943,200
+278,200
| +4% | +$18.1M | 3.81% | 8 |
|
|
2015
Q2 | $448M | Buy |
6,665,000
+1,850,100
| +38% | +$121M | 3.74% | 5 |
|
|
2015
Q1 | $282M | Sell |
4,814,900
-516,200
| -10% | -$31.2M | 2.41% | 13 |
|
|
2014
Q4 | $349M | Sell |
5,331,100
-146,900
| -3% | -$9.26M | 3.33% | 7 |
|
|
2014
Q3 | $316M | Buy |
5,478,000
+273,800
| +5% | +$15.2M | 3.3% | 7 |
|
|
2014
Q2 | $294M | Buy |
5,204,200
+410,400
| +9% | +$21.5M | 3.45% | 4 |
|
|
2014
Q1 | $246M | Buy |
4,793,800
+1,032,900
| +27% | +$52.2M | 3.03% | 8 |
|
|
2013
Q4 | $199M | Buy |
3,760,900
+2,018,900
| +116% | +$99.2M | 2.92% | 10 |
|
|
2013
Q3 | $77.9M | Sell |
1,742,000
-35,000
| -2% | -$1.55M | 1.39% | 25 |
|
|
2013
Q2 | $73.5M | Buy |
+1,777,000
| New | +$77.7M | 1.56% | 25 |
|
Other funds holding ABBV
OrbiMed's ABBV Position: Q4 2023 in Review
OrbiMed sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 330,000 shares — an estimated $49.2M sold.
OrbiMed first reported a position in ABBV in Q2 2013 and held it in 32 quarters. The position peaked at $448M in Q2 2015. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.
- OrbiMed reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
- OrbiMed sold 330,000 AbbVie shares in Q4 2023, an estimated $49.2M.
- OrbiMed first reported a position in AbbVie in Q2 2013 and held it in 32 quarters.
- OrbiMed's AbbVie position peaked at $448M in Q2 2015.
- 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.
Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.